First Results of the DEB-AMI (Drug Eluting Balloon in Acute ST-Segment Elevation Myocardial Infarction) Trial A Multicenter Randomized Comparison of Drug-Eluting Balloon Plus Bare-Metal Stent Versus Bare-Metal Stent Versus Drug-Eluting Stent in Primary Percutaneous Coronary Intervention With 6-Month Angiographic, Intravascular, Functional, and Clinical Outcomes by Belkacemi, Anouar et al.
Journal of the American College of Cardiology Vol. 59, No. 25, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00First Results of the DEB-AMI (Drug Eluting Balloon in
Acute ST-Segment Elevation Myocardial Infarction) Trial
A Multicenter Randomized Comparison of Drug-Eluting Balloon Plus
Bare-Metal Stent Versus Bare-Metal Stent Versus Drug-Eluting Stent
in Primary Percutaneous Coronary Intervention With 6-Month
Angiographic, Intravascular, Functional, and Clinical Outcomes
Anouar Belkacemi, MD,* Pierfrancesco Agostoni, MD, PHD,* Hendrik M. Nathoe, MD, PHD,*
Michiel Voskuil, MD, PHD,* ChunLai Shao, MD,* Eric Van Belle, MD, PHD,*
Thierry Wildbergh, MD,* Luigi Politi, MD,† Pieter A. Doevendans, MD, PHD,*
Giuseppe M. Sangiorgi, MD,† Pieter R. Stella, MD, PHD*
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Objectives The goal of this study was to compare angiographic, intravascular imaging, and functional parameters, as well
as the clinical outcomes of patients treated with drug-eluting balloon (DEB) plus bare-metal stent (BMS) versus
BMS versus drug-eluting stent (DES) for ST-segment elevated acute myocardial infarction (STEMI).
Background Concerns remain regarding the long-term safety of DES in STEMI. DEB could provide an attractive alternative in
order to achieve potentially similar effectiveness but limiting the long-term hazards related to late-acquired stent
malapposition and thus stent thrombosis.
Methods In this randomized, international, 2-center, single-blinded, 3-arm study, STEMI patients were randomly assigned
to group A: BMS; group B: DEB plus BMS; or group C: DES after successful thrombus aspiration. The primary end-
point was 6-month angiographic in-stent late-luminal loss. Secondary endpoints were in-stent binary restenosis,
major adverse cardiac events (MACE: cardiac death, myocardial infarction, target vessel revascularization). In a
subgroup of patients, stent (mal)apposition (by optical coherence tomography) and endothelial function (by ace-
tylcholine infusion) was assessed.
Results Overall, 150 patients were randomized. Procedural success was achieved in 96.7%. In groups A, B, and C,
respectively, late-luminal loss was 0.74  0.57 mm, 0.64  0.56 mm, and 0.21  0.32 mm (p  0.01);
binary restenosis was 26.2%, 28.6%, and 4.7% (p  0.01); and MACE rates were 23.5%, 20.0%, and 4.1%
(p  0.02), respectively. The median percentage [25th to 75th interquartile range] of uncovered and malap-
posed stent struts per lesion was 0 [0 to 0.35], 2.84 [0 to 6.63], and 5.21 [3.25 to 14.5] (p  0.01). Signif-
icant paradoxical vasoconstriction was seen in groups B and C.
Conclusions In STEMI patients, DEB followed by BMS implantation failed to show angiographic superiority to BMS only. Angio-
graphic results of DES were superior to both BMS and DEB. Moreover, DEB before implantation induced more
uncovered and malapposed stent struts than BMS, but less than after DES. (Drug-Eluting Balloon in Acute Myo-
cardial Infarction [DEB-AMI]; NCT00856765) (J Am Coll Cardiol 2012;59:2327–37) © 2012 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.02.027Primary percutaneous coronary intervention (PCI) for the
treatment of patients with ST-segment elevation myocardial
infarction (STEMI) is well established (1). In this setting,
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than in routine clinical practice,
partly due to protocol-mandated
angiographic follow-up (2). More-
over, in patients without risk fac-
tors for restenosis such as diabetes
mellitus, reference vessel diameter
3.0 mm, and lesion length 20
mm, DES and BMS result in
similar revascularization rates (2).
Furthermore, with the use of
DES in the STEMI setting, safety
concerns remain regarding late ac-
quired stent malapposition with
consequently a possible increased
risk of stent thrombosis (3). It is
known that DES induce local
inflammation due to the presence
of polymers, drug-induced de-
layed endothelial healing, and
vessel wall toxicity. Besides, in
STEMI, the culprit lesions usu-
ally show a large necrotic core
and high amount of thrombus
formation, characteristics that
an cause even more local toxicity, inflammation, and
elayed vascular healing after DES implantation (4,5).
hese effects are also associated with an impaired vasomotor
unction in the treated vessel (6,7).
The paclitaxel drug-eluting balloon (DEB) is an emerg-
ng device that has shown promising results (8–11) by
eans of a high-concentration, rapid local release of an
ntirestenotic drug (paclitaxel) into the coronary vessel
ithout using durable polymers (12). Therefore, it could
rovide a valid alternative treatment in STEMI patients by
voiding sustained drug/polymer interaction with the vessel
all.
The aim of the current study was to test the DIOR DEB
Eurocor, Bonn, Germany) combined with a modern cobalt
hromium BMS in primary PCI with the goal of obtaining
mproved angiographic results and comparable vessel heal-
ng and preserved endothelial function with respect to BMS
lone and less uncovered or malapposed stent struts than a
aclitaxel-eluting DES.
ethods
he DEB-AMI (Drug Eluting Balloon in Acute Myocar-
ial Infarction) trial was a randomized, international,
-center, single-blinded, 3-arm study, aimed at comparing
MS implantation (group A), versus sequential DEB dila-
ation and BMS implantation (group B) and paclitaxel DES
mplantation (group C) in patients presenting with STEMI.
n order to minimize confounding, in both group A and B,
n identical stent platform was used, and the same drug
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DEB  drug-eluting
balloon(s)
DES  drug-eluting stent(s)
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
MLD  minimal luminal
diameter
OCT  optical coherence
tomography
PCI  percutaneous
coronary intervention
QCA  quantitative
coronary angiography
STEMI  ST-segment
elevation myocardial
infarction
TLR  target lesion
revascularization
TVR  target vessel
revascularizationpaclitaxel) was compared in groups B and C.The study, conducted according to the Declaration of
elsinki, was approved by the ethics committees of both
articipating centers, and signed informed consent was
btained from all included patients.
atient selection. Patients between 18 and 80 years of age,
resenting in the first 12 h after the onset of STEMI
diagnosed by the presence of anginal symptoms associated
ith electrocardiographic ST-segment elevation of 1 mm
n 2 contiguous leads or new left bundle branch block),
nd undergoing primary PCI, with angiographic evidence of
single culprit lesion in the target vessel, after successful
hrombus aspiration (defined by no angiographically evident
ow-limiting residual thrombus at the site of [sub]occlu-
ion, and Thrombolysis In Myocardial Infarction [TIMI]
ow grade 1) were deemed eligible for inclusion.
Major clinical and procedural exclusion criteria were
ontraindications to study medications (acetylsalicylic acid,
lopidogrel, paclitaxel), life expectancy 12 months, lesion
ength 25 mm, reference vessel diameter 2.5 mm and
4.0 mm, severe triple vessel disease, left main stenosis
50%, and a combination of type C coronary lesion and
iabetes mellitus (in which DES was favored).
evices. The DEB used in this study was the second-
eneration DIOR coronary angioplasty balloon (8). This
EB has a coating consisting of a 1:1 mixture of paclitaxel
ith shellac applied to the balloon by a micro-pipetting
rocedure. This device is coated with 3 g of paclitaxel/
mm2 of balloon surface. The DIOR DEB is available in the
ollowing lengths: 15, 20, 25, and 30 mm; and diameters:
.0, 2.25, 2.5, 2.75, 3.0, 3.5, and 4.0 mm. The shellac
oating protects the drug from a wash-off effect during
racking in the guiding catheter and in the coronary vascu-
ature. The minimal inflation time is 30 s (recommended 45
o 60 s) to allow sufficient drug release into the vessel wall in
rder to achieve the required effective tissue dosages of
aclitaxel to inhibit smooth muscle cell proliferation (12).
The BMS (Genius Magic stent, Eurocor) is a new cobalt
hromium stent platform with a strut thickness of 60 m.
he DES (Taxus Liberté, Boston Scientific, Natick, Mas-
achusetts) has a stainless steel stent platform coated with a
ermanent polymer that allows the release of paclitaxel (1
g/mm2). The total strut thickness including stent and
polymer is 132 m.
Randomization and interventional procedure. All pa-
tients received routinely in the ambulance or at the first
medical contact a loading dose of acetylsalicylic acid (325 to
500 mg) and of clopidogrel (600 mg). Heparin was admin-
istered before and during the procedure in order to maintain
an activated clotting time 250 s. Additional administra-
tion of glycoprotein IIb/IIIa inhibitors was recommended,
but was left to the physician’s discretion.
After fulfilling angiographic inclusion criteria, patients
underwent mandated thrombus aspiration of the culprit
lesion with a manual thrombus aspiration device. Sequen-
tially, if thrombus aspiration was successful according to
definition, patients were randomly assigned to 1 of the 3
2329JACC Vol. 59, No. 25, 2012 Belkacemi et al.
June 19/26, 2012:2327–37 Drug-Eluting Balloon in STEMItreatment strategies: group A: pre-dilation with a standard
balloon (balloon-to-artery ratio 0.8:1) followed by BMS
implantation; group B: pre-dilation with a standard balloon
(balloon-to-artery ratio 0.8:1) followed by sequential dila-
tion with DEB (balloon-to-artery ratio 1:1 and at least 5
mm longer than the normal balloon in order to avoid
geographic miss) for at least 30 s, and BMS implantation; or
group C: pre-dilation with a standard balloon (balloon-to-
artery ratio 0.8:1) followed by implantation of a paclitaxel-
eluting DES. Randomization was obtained by means of
sequentially numbered, opaque sealed envelopes containing
the assigned group letter (A, B, or C). The coupling
between number of the envelope and group letter was
automatically generated by a computer, and the envelopes
were sealed by an independent employee. The allocation
ratio to the 3 groups was 1:1:1.
Concerning the DEB use, a 1:1 balloon-to-artery ratio,
nominal inflation pressures, and an inflation time of 30 s
were mandated. Special care was taken to center the DEB in
the lesion and to use a DEB at least 5 mm longer than the
normal balloon used and the intended stent length, in order
to avoid potential geographic miss (13). In any group,
additional bailout stenting (with stents of the same random-
ization group) was performed in case of residual edge
dissections or incomplete lesion coverage. In this setting in
group B, additional DEB were also mandated to cover the
complete stented segment. In case of multiple DEB use,
care was taken to avoid excessive DEB overlap (to avoid
double-dose release). Additional post-dilation was left to
the physician’s discretion. Discharge medications included
acetylsalicylic acid 80 to 100 mg per day lifelong and
clopidogrel 75 mg for 12 months.
Follow-up and clinical endpoints. All patients were con-
tacted by phone call 1 month after the procedure and
underwent clinical and angiographic follow-up at 6 months.
In case an event occurred, detailed review of the related
hospital files was performed.
Major adverse cardiac events (MACE) were defined as a
hierarchical composition of death, any myocardial infarction
(MI), and target vessel revascularization (TVR). All defini-
tions followed the Academic Research Consortium criteria
(14). Target lesion revascularization (TLR) was defined as
any repeat percutaneous or surgical intervention due to a
restenosis in the treated segment (including the stent and 5
mm proximal and distal). A TLR was considered clinically
indicated in case of restenosis 50% by quantitative coro-
nary angiography (QCA), associated with recurrent angina
and/or objective signs of silent ischemia (stress tests or
fractional flow reserve), or in case of restenosis 70% by
QCA without the aforementioned signs or symptoms. Stent
thrombosis was defined as a definite, probable, or possible
and early or late, also according to the Academic Research
Consortium criteria (14). Angiographic success was defined
as achievement of a TIMI flow grade 3 and final residual
stenosis 30%, using any percutaneous method. Device
success was defined as angiographic success using therandomized device. Procedural success was defined as an-
giographic success without the occurrence of in-hospital
MACE. All patients’ files were independently monitored
and all outcomes were adjudicated by an independent
clinical events committee.
Quantitative coronary angiography. QCA was performed
according to standard procedures (15), using dedicated
software (CAAS 5.9.1 research edition, Pie Medical Imag-
ing, Maastricht, the Netherlands). Images were analyzed by
an independent core laboratory with operators not involved
with the procedure and blinded to randomization assign-
ment. As the vessel was totally occluded in most of the
baseline images, the pre-procedural images analyzed were
those after thrombus aspiration. The number of patients
with a total occlusion was assessed, and the values for
diameter stenosis and minimal luminal diameter (MLD)
were changed in these patients in 100% and 0 mm,
respectively. In the post-procedural and follow-up images,
the stent(s) and additional 5-mm segments proximal and
distal to the stent(s) edges were analyzed. MLD and lesion
length were directly measured by the QCA software,
whereas reference vessel diameter was estimated by an
interpolation method, and percent diameter stenosis was
subsequently computed. Binary restenosis was defined as a
diameter stenosis 50% at angiographic follow-up. Late-
luminal loss was defined as the difference between post-
procedural MLD and MLD at follow-up in the same
segment (proximal to the stent, in-stent, distal to the stent,
in-segment). In-stent late-luminal loss was the primary
endpoint of the study.
Optical coherence tomography. At the same time as the
main randomization, each patient was also randomized to
undergo, at 6 months, only angiographic follow-up or
optical coherence tomography (OCT) investigation and
endothelial function testing together with the angiographic
control (4:1 ratio).
Time-domain or frequency-domain OCT systems (M3
LightLab Imaging, Westford, Massachusetts, or C7XR, St.
Jude Medical, St. Paul, Minnesota) were used. All images
were analyzed by an independent core laboratory.
OCT imaging of the target lesion was obtained after
200-g intracoronary nitroglycerin infusion, and OCT
pullback images were acquired during continuous infusion
of contrast from the guiding catheter, by means of a
controlled injection (2 to 4 ml/s contrast with 200 to 300
psi, depending on the coronary assessed), as previously
described (16). Images were acquired with automated pull-
back at a rate of 2, 3, or 20 mm/s (according to the type of
OCT system). All cross-sectional images (frames) were
initially screened for quality assessment and excluded if any
portion of the stent was out of the screen, images were not
analyzable due to side branches, or images had poor quality
caused by residual blood, artifacts, or reverberation (17).
A dedicated semiautomated contour-detection system
(Curad BV, Wijk bij Duurstede, the Netherlands) was used.
Two contours were delineated: the lumen contour (for each
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Drug-Eluting Balloon in STEMI June 19/26, 2012:2327–37cross-sectional image) and the stent contour (every 0.2 to
0.3 mm, depending on the pullback speed, thus, for exam-
ple, every 5 frames for 2 to 3 mm/s). For stent analysis, an
automated stent contour interpolation was performed be-
tween frames. Manual corrections were applied if needed.
Lumen, stent, and neointimal hyperplasia diameters, areas,
and volumes were automatically calculated. Stent struts were
semiautomatically classified as covered embedded, covered
protruding, uncovered apposed, and malapposed. Covered
embedded struts were defined as covered by tissue and not
otherwise interrupting the smooth lumen contour; covered
protruding struts were defined as covered with tissue but
extending into the lumen (however, not greater than the
stent strut thickness: 132 m for DES and 60 m for
MS); uncovered apposed struts were defined by the same
istance from the lumen border as covered protruding
truts, without the presence of tissue coverage, however;
alapposed struts were defined as those not abutting the
umen border: 132 m for DES and 60 m for BMS
18). The distance was measured between the center of the
tent strut and the lumen border, and was preset in the
oftware and manually corrected if necessary. Hence, all
truts were semiautomatically defined depending on their
istance.
ndothelial function testing. The assessment of the
ndothelium-dependent vasomotor function was performed
y the selective infusion of the endothelium-dependent
asodilator acetylcholine into the target coronary artery.
fter baseline angiography, acetylcholine was infused via an
nfusion microcatheter located at the level of the stent into
he target coronary artery at incremental concentrations of
06, 105, and 104 mol/l/ml. Acetylcholine was infused
or 3 min at each concentration, with a 3-min interval
etween each infusion. Angiography was obtained after
ach infusion. The infusion was terminated when the largest
ose of acetylcholine was reached or in case of coronary
asoconstriction 50% by visual estimation. Nitroglycerin
as then injected as an intracoronary bolus (100 g)
hrough the guiding catheter to evaluate the endothelium-
ndependent coronary vasoactive response of the coronary
rtery. Angiography was also performed after nitroglycerin
nfusion.
Coronary responses to acetylcholine and nitroglycerin
ere analyzed offline, using dedicated QCA software allow-
ng for segmental analysis by the same core laboratory. All
mages were recorded in identical gantry position, allowing
or accurate consecutive analysis, and were analyzed during
iastole. The images obtained at baseline and after each
nfusion were analyzed for MLD in consecutive 5-mm
egments, distal to the stent. Shoulder patterns on QCA
nalysis were used to identify the distal stent edge (15). The
rst 15 mm were considered in the analysis, and the worst
LD per each 5-mm segment was chosen. The MLD
btained after each infusion was compared with baseline
alues. Baseline MLD was set as 0. Endothelial function was
uantified as percentage change of MLD from baseline, with segative values expressing paradoxical vasoconstriction and
ositive values representing physiological vasodilatation.
tatistical analysis. The primary endpoint of the study was
n-stent late-luminal loss. The sample size calculation was
ased on the direct comparison between BMS (group A)
nd DEB plus BMS (group B). The study tested the
ypothesis that late-luminal loss in group B would be
ignificantly better than in group A. A sample size of 43
ubjects per group was estimated to show a significant
eduction in late-luminal loss of 50% (from 0.70 to 0.35
m) with a 2-tailed p value of 0.05 and a power of 90%,
ssuming a standard deviation of 0.50 mm. To accommo-
ate a 15% loss in angiographic follow-up, 50 patients per
roup were enrolled. A third DES arm with the same
umber of patients was added as an exploratory arm, to test
t the same time this device in the same setting. Concerning
CT and endothelial function, the number of patients for
he substudy was 10 per group, and the substudy was
pecifically powered (Online Appendix).
Continuous variables are presented as mean  SD if
normally distributed, or median [interquartile range] if not
normally distributed. Categorical variables are presented as
counts and percentages. Continuous variables were com-
pared between 2 groups using the Student t test or its
nonparametric equivalent Mann-Whitney U test. In case of
a between-groups comparison (A vs. B vs. C), analysis of
variance or its nonparametric equivalent Kruskal-Wallis test
was applied. Categorical variables were compared using the
chi-square or Fischer exact test. All analyses were performed
according to the intention-to-treat principle. A 2-tailed
value of 0.05 was considered statistically significant.
esults
atient and procedural characteristics. Overall, 150 pa-
ients were included and underwent primary PCI for
TEMI according to the protocol between February 2009
nd November 2010 (Fig. 1). Baseline clinical characteris-
ics are shown in Table 1. Procedural and angiographic
haracteristics are shown in Tables 2 and 3.The groups were
ell balanced for all variables. Both angiographic and device
uccess were achieved in 50 (98.0%), 49 (98.0%), 48
98.0%), and procedural success in 49 (96.1%), 48 (96.0%),
8 (98.0%) of patients in the BMS, DEB, and DES groups,
espectively (overall p  1.00 and p  0.83, respectively).
n-hospital adverse events. Two MACE occurred during
ospitalization. A subacute stent thrombosis occurred 4
ays post-procedure in a 61-year-old man randomized to
roup B. This caused a recurrent MI and a TLR with
uccessful thrombus aspiration and implantation of an
dditional BMS distal to the previous stent placed because
f a missed edge dissection after the index treatment. This
atient was initially treated with a single BMS that was
re-dilated (before DEB) with a normal balloon. The
econd patient, randomized to group A, was an 86-year-old
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June 19/26, 2012:2327–37 Drug-Eluting Balloon in STEMIwoman who died 1 day post-procedure due to cardiogenic
shock, developed shortly after the index procedure.
Angiographic follow-up. At 6 months, 23 patients (15%)
did not undergo angiographic control: 19 refused due to lack
of symptoms, 2 patients died before angiographic follow-up,
and 2 patients were recommended not to undergo it for
clinical reasons (renal failure and intracranial hemorrhage
with severe sequelae). Hence, 6-month QCA was available
in 43 (84.3%), 42 (84.0%), and 42 (85.7%) group A, B, and
C patients, respectively (overall p  0.75).
The QCA data are presented in Table 3. The primary
endpoint, reduction of in-stent late-luminal loss, was not
Figure 1 Flow Chart of the Study
Patients with ST-segment elevation myocardial infarction (STEMI) were included if
going primary percutaneous coronary intervention (PCI), 891 were not randomly as
the 3 treatment groups. BMS  bare-metal stent(s); DEB  drug-eluting balloon(s
Baseline Characteristics of the Patients and LeTable 1 Baseline Characteristics of the Pat
(n
Age, yrs 59.9
Male 42
Risk factors
Diabetes mellitus 6
Hyperlipidemia 11
Current smoker 29
Hypertension 18
Previous myocardial infarction
Previous percutaneous coronary intervention 1
Previous coronary bypass surgery
Time from symptom onset to hospital arrival, min 125
Time from hospital arrival to treatment, min 40
Location of the myocardial infarction
Anterior 19
Inferior 25
Lateral 3
Posterior 3
Killip class II/III 1Values are mean  SD, n (%), or median [25th–75th interquartile range].
BMS  bare-metal stent(s); DEB  drug-eluting balloon; DES  drug-elutinmet: 0.74  0.57 mm in group A versus 0.64  0.56 mm
n group B (p  0.39). Late-luminal loss in group C was
ignificantly less compared with both groups A and B:
.21  0.32 mm (overall p  0.01).
No significant differences were shown in binary restenosis
ates between groups A (26.2%) and B (28.6%), whereas
roup C (4.7%) showed a significantly lower rate compared
ith the other groups (overall p  0.01).
dverse events at 6-month follow-up. Clinical events are
hown in Table 4. A total of 28 MACE occurred in 24
atients. In group A, 12 (23.5%) patients had a MACE: 9
17.6%) TLR (all due to restenosis and all treated with
resented within 12 h after the onset of symptoms. Of the 1,041 patients under-
to a treatment group. The remaining 150 patients were randomized to one of
 drug-eluting stent(s); MI  myocardial infarction.
in the 3 Groupsand Lesions in the 3 Groups
DEB
(n  50)
DES
(n  49)
p Value
DEB vs. BMS
.9 59.7 9.9 55.9 9.7 0.92
) 41 (82.0) 41 (83.7) 0.96
) 3 (6.0) 2 (4.1) 0.49
) 13 (26.0) 16 (32.7) 0.60
) 19 (38.0) 28 (57.1) 0.07
) 17 (34.0) 15 (30.6) 0.89
1 (2.0) 2 (4.1) 0.50
1 (2.0) 2 (4.1) 0.99
0 0 —
0] 121 [89–192] 114 [76–238] 0.58
] 35 [25–80] 30 [20–72] 0.64
0.78
) 23 (46.0) 17 (34.7)
) 22 (44.0) 24 (49.0)
3 (6.0) 4 (8.2)
2 (4.0) 4 (8.2)
1 (2.0) 2 (4.1) 0.99they p
signed
); DESsionsients
BMS
 51)
 10
(82.4
(11.8
(21.6
(56.9
(35.3
0
(2.0)
0
[66–20
[25–80
(37.3
(49.0
(5.9)
(5.9)
(2.0)g stent(s).
ge].
s in Ta
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Drug-Eluting Balloon in STEMI June 19/26, 2012:2327–37repeated PCI), 1 (2.0%) TVR non-TLR (due to disease
progression), and 2 (3.9%) cardiac deaths (the first due to
cardiogenic shock, shortly after the index procedure as
already described, and the second after 5 months because of
progressive heart failure). In group B, MACE occurred in
10 (20.0%) patients. Ten (20.0%) cases of TLR were
reported: 8 due to restenosis and all treated percutaneously,
and 2 due to early definite stent thrombosis. The first was a
subacute stent thrombosis 4 days post-procedural, as has
been already described. The second occurred 5 days after the
index procedure, causing a recurrent MI treated with
successful thrombus aspiration and balloon redilation of the
previous stent, probably undersized. This patient was ini-
tially treated with a single BMS without pre-dilation with a
Baseline Characteristics of the Procedures in thTable 2 Baseline Characteristics of the Pro
BMS
(n  5
Radial approach 22 (43
Target vessel
Left anterior descending/diagonal 21 (41
Circumflex/marginal branch 8 (15
Right coronary artery/posterior descending 22 (43
Baseline TIMI flow grade
0 or 1 43 (84
2 or 3 8 (15
Pre-dilation with standard balloon 51 (10
Pre-dilation balloon diameter, mm 2.5
Pre-dilation balloon length, mm 15.8
Pre-dilation balloon pressure, atm 11.9
DEB diameter, mm —
DEB length, mm —
DEB pressure, atm —
DEB inflation time, s —
Number of stents implanted per lesion 1.3
Number of stents implanted per lesion
1 37 (72
2 13 (25
2 1 (2.
Stent diameter, mm 2.94
Total stent length, mm 25.3
Post-dilation with standard balloon 18 (35
Post-dilation balloon diameter, mm 3.2
Post-dilation balloon length, mm 13.2
Maximum inflation pressure per lesion, atm 16.9
Final TIMI flow grade
0 or 1 0
2 1 (2.
3 50 (98
Glycoprotein IIb/IIIa inhibitor 41 (80
Contrast use, ml 170 [150
Fluoroscopy time, min 8 [7–1
Procedural time, min 46 [40–
Angiographic success 50 (98
Procedural success 49 (96
Values are n (%), mean  SD, or median [25th–75th interquartile ran
TIMI  Thrombolysis In Myocardial Infarction; other abbreviations anormal balloon. Further, 1 (2.0%) TVR non-TLR (due todisease progression) and 2 (4.0%) MI (both caused by stent
thrombosis as previously mentioned) occurred. In the DES
group, 1 (2.0%) TLR (due to restenosis and treated percu-
taneously) and 1 (2.0%) TVR non-TLR (due to disease
progression) occurred in 2 patients. Finally, in 2 patients,
both in the DEB group, repetitive events of the same type
occurred in the first 6 months. The first patient had a stent
thrombosis 5 days post-procedure, causing an MI and TLR
(as previously described), and underwent a new TLR
because of restenosis 3 months later. The second patient
underwent a clinically driven TLR because of restenosis at
10 weeks and again at 6 months.
OCT and endothelial function testing. After the index
procedure, 31 patients were randomized to undergo OCT
roupses in the 3 Groups
DEB
(n  50)
DES
(n  49)
p Value
DEB vs. BMS
20 (40.0) 20 (40.8) 0.75
0.16
24 (48.0) 18 (36.7)
13 (26.0) 11 (22.4)
13 (26.0) 20 (40.1)
0.28
34 (68.0) 27 (55.1)
16 (32.0) 22 (44.9)
30 (60.0) 49 (100) 0.01
2.2 0.4 2.4 1.1 0.29
16.5 5.3 16.2 4.6 0.59
12.1 3.2 12.3 3.3 0.86
3.0 0.5 — —
23.4 3.7 — —
10.9 3.3 — —
44.1 14.4 — —
1.3 0.7 1.2 0.5 0.77
0.42
40 (80.0) 40 (81.6)
9 (18.0) 8 (16.3)
1 (2.0) 1 (2.0)
2.98 0.52 2.88 0.44 0.71
24.4 13.4 25.4 13.3 0.69
18 (36.0) 14 (28.6) 0.88
3.1 0.7 3.3 0.5 0.47
14.3 4.2 14.0 6.1 0.43
15.9 2.3 16.8 2.7 0.08
0.99
0 0
1 (2.0) 1 (2.0)
49 (98.0) 48 (98.0)
43 (86.0) 39 (79.6) 0.64
190 [150–240] 160 [120–210] 0.27
9 [7–17] 8 [6–10] 0.17
51 [44–70] 40 [34–50] 0.18
49 (98.0) 48 (98.0) 0.99
48 (96.0) 48 (98.0) 0.98
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the death of 1 patient before the follow-up procedure.
During the 6-month angiographic follow-up, 27 patients
underwent OCT and 21 patients underwent endothelial
function testing. Thus, of these 31 randomized patients,
3 refused angiographic follow-up and 1 died before it. In
an additional 6 patients, only OCT was performed,
Quantitative Coronary Angiography of the CulpriTable 3 Quantitative Coronary Angiography
BMS
Pre-procedure
Lesions 51
Reference vessel diameter, mm 2.84 0
Minimal luminal diameter before any
intervention, mm
0.16 0
Diameter stenosis before any intervention, % 94.1 1
Minimal luminal diameter, mm* 0.74 0
Diameter stenosis, %* 74.1 1
Lesion length, mm* 16.20 9
Post-procedure
Lesions 51
Minimal luminal diameter, mm 2.47 0
Diameter stenosis, % 14.1 7
Follow-up
Lesions 42
Minimal luminal diameter, mm 1.68 0
Diameter stenosis, % 41.2 2
Late-luminal loss, mm
Proximal 0.22 0
In-stent 0.74 0
Distal 0.01 0
In-segment 0.52 0
Binary restenosis in-stent 10 (23
Binary restenosis in-segment 10 (23
Values are n, mean  SD, or n (%). *Measured after opening the culp
Abbreviations as in Table 1.
Clinical Outcomes at 6 MonthsTable 4 Clinical Outcomes at 6 Months
BM
(n 
Events at 1-month follow-up
Cardiac death 1*(2.
Myocardial infarction 0
Target lesion revascularization 0
Target vessel non-lesion revascularization 0
Stent thrombosis 0
Cumulative events at 6-month follow-up
Cardiac death 2 (3.
Myocardial infarction 0
Target lesion revascularization 9 (17
Target vessel non-lesion revascularization 1 (2.
Stent thrombosis 0
Major adverse cardiac events 12 (23
Values are n (%). *Event occurred in-hospital. †Of these 2 patients,
revascularization in-hospital.
Abbreviations as in Table 1.without endothelial function testing: in 3 patients, severe
in-stent restenosis was evident, in 2, the temporary
pacemaker lead (routinely placed during this test for
safety purposes) could not be placed, and in 1, a new
severe lesion distal to the stent was detected. The OCT
and endothelial function findings at 6-month follow-up
are presented in Table 5.
ions Treated in the 3 Groupse Culprit Lesions Treated in the 3 Groups
DEB DES
p Value
DEB vs.
BMS
DEB vs. BMS
vs. DES
50 49
2.84 0.41 2.78 0.53 0.99 0.78
0.20 0.30 0.34 0.41 0.57 0.03
92.4 11.4 88.4 13.6 0.47 0.03
0.62 0.32 0.64 0.38 0.09 0.14
78.8 11.9 77.3 12.8 0.05 0.03
18.7 13.1 16.8 8.7 0.28 0.41
50 49
2.50 0.49 2.53 0.41 0.75 0.87
14.1 9.6 12.2 8.6 1.00 0.65
42 43
1.86 0.74 2.31 0.42 0.25 0.01
35.7 20.9 19.0 11.6 0.26 0.01
0.27 0.45 0.16 0.43 0.67 0.69
0.64 0.56 0.21 0.32 0.39 0.01
0.12 0.48 0.07 0.44 0.30 0.74
0.44 0.55 0.17 0.35 0.51 0.02
12 (28.6) 2 (4.7) 0.67 0.01
13 (31.0) 3 (7.0) 0.51 0.02
n.
DEB
(n  50)
DES
(n  49)
p Value
DEB vs. BMS
0 0 0.32
2†(4.0) 0 0.24
2†(4.0) 0 0.24
0 0 —
2†(4.0) 0 0.24
0 0 0.16
2 (4.0) 0 0.24
10 (20.0) 1 (2.0) 0.76
1 (2.0) 1 (2.0) 0.99
2 (4.0) 0 0.24
10 (20.0) 2 (4.1) 0.67
nt had a stent thrombosis, myocardial infarction, and target lesiont Lesof th
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stent struts per lesion was 0% [0 to 0.35], 2.84% [0 to 6.63],
and 5.21% [3.25 to 14.5] in groups A, B, and C, respectively
(overall p  0.01). On cross-sectional analysis, vessel size
was not statistically different between groups with stent
diameters of 3.57 [2.75 to 3.77], 3.07 [2.75 to 3.40], and
3.19 [2.92 to 3.34] mm in the BMS, DEB, and DES
groups, respectively (overall p  0.25). Moreover, the stent
length was also not statistically different between groups
25.3 [19.2 to 35.3], 22.9 [18.3 to 28.3], and 19.4 [14.5 to
27.9] mm, respectively (overall p  0.42). Maximum
eointimal area and neointimal volume were higher in the
OCT and Endothelial Function, Follow-Up at 6 MonthsTable 5 OCT and Endothelial Function, Follow-Up at 6 Months
BMS
Cross-section analyses
Lesions 8
Stent length analyzed 25.25 [19.19 to 35.33
Minimal mean lumen diameter, mm 1.76 [1.45 to 2.23]
Minimal mean stent diameter, mm 3.01 [2.25 to 3.41]
Minimal lumen area, mm2 3.22 [1.96 to 4.97]
Minimal stent area, mm2 7.78 [4.56 to 10.43]
Maximum neointimal area, mm2 6.25 [4.53 to 9.37]
Lumen volume, mm3 124.0 [91.1 to 224.3]
Lumen volume per mm, mm3 6.26 [3.35 to 8.19]
Stent volume, mm3 204.6 [193.9 to 380.0
Stent volume per mm, mm3 10.91 [6.34 to 11.98]
Neointimal volume, mm3 101.3 [63.5 to 101.3]
Neointimal volume per mm, mm3 3.78 [2.73 to 5.72]
Malapposition volume, mm3 0.00 [0.00 to 0.13]
Malapposition volume per mm, mm3 0.00 [0.00 to 0.01]
Strut analyses
Total no. struts analyzed 3,529
Covered embedded struts per lesion, % 100 [99.0 to 100]
Covered protruding struts per lesion, % 0 [0 to 0.84]
Uncovered struts per lesion, % 0 [0 to 0]
Malapposed struts per lesion, % 0 [0 to 0.35]
Covered struts overall (embedded and protruding)
per lesion
100 [99.6 to 100]
Uncovered struts overall (uncovered embedded
and malapposed) per lesion
0 [0 to 0.35)
Endothelial function
Lesions 5
Baseline (0–15 mm) 1.92 [1.30 to 2.83]
Low acetylcholine (0–15 mm) 2.07 [1.35 to 2.98]
Medium acetylcholine (0–15 mm) 1.72 [1.21 to 2.81]
High acetylcholine (0–15 mm) 1.91 [1.09 to 2.50]
Post-nitroglycerin (0–15 mm) 1.78 [1.38 to 2.61]
Maximum MLD change after acetylcholine (0–5 mm) 2.86 [26.1 to 11.0]
MLD change after nitroglycerine (0–5 mm) 1.94 [13.0 to 14.6]
Maximum MLD change after acetylcholine (5–10 mm) 7.92 [29.7 to 13.8]
MLD change after nitroglycerine (5–10 mm) 10.0 [13.9 to 18.7]
Maximum MLD change after acetylcholine (10–15 mm) 5.61 [32.1 to 22.3]
MLD change after nitroglycerine (10–15 mm) 10.4 [14.0 to 27.8]
Values are n or median [25th–75th interquartile range].
MLD  minimal luminal diameter; OCT  optical coherence tomography; other abbreviations aMS group, compared with DEB and DES: 6.25 [4.53 to.37], 4.91 [4.23 to 5.28], and 2.70 [1.97 to 3.52] mm2
(overall p  0.01) and 101.3 [63.5 to 101.3], 60.0 [46.7 to
80.4], and 24.2 [11.5 to 47.4] mm3 (overall p  0.01),
respectively.
Concerning endothelial function, no effect was seen in
the BMS group, with substantial stability of the vascular
dimensions. By contrast, both DEB and DES showed a
paradoxical vasoconstriction related to incremental doses of
acetylcholine. The degree of endothelial-dependent vascular
response to incremental acetylcholine doses, expressed as
percentage change of in-segment MLD, was significantly
diminished in the DES group in comparison to the control
DEB DES
p Value
BMS vs. DEB DEB vs. DES
10 9
.85 [18.33 to 28.28] 19.35 [14.45 to 27.85] 0.48 0.46
.66 [1.32 to 1.92] 2.22 [2.00 to 2.52] 0.53 0.01
.56 [2.28 to 2.91] 2.62 [2.52 to 2.84] 0.18 0.46
.96 [1.73 to 3.88] 5.36 [4.81 to 7.01] 0.79 0.03
.54 [4.94 to 8.12] 7.62 [6.54 to 8.10] 0.25 0.05
.91 [4.23 to 5.28] 2.70 [1.97 to 3.52] 0.11 0.01
9.6 [89.6 to 155.9] 139.0 [125.6 to 221.4] 0.66 0.17
.04 [4.09 to 7.76] 8.08 [6.80 to 8.83] 0.66 0.03
9.4 [161.3 to 212.8] 166.1 [142.1 to 260.4] 0.09 0.51
.10 [6.44 to 10.18] 9.11 [8.42 to 9.97] 0.33 0.29
0.0 [46.7 to 80.4] 24.2 [11.5 to 47.4] 0.04 0.01
.75 [1.77 to 3.44] 1.07 [0.77 to 1.66] 0.05 0.01
.53 [0.02 to 3.55] 1.71 [0.96 to 4.08] 0.07 0.17
.02 [0.00 to 0.20] 0.11 [0.05 to 0.18] 0.06 0.10
5,251 4,925
5.5 [92.0 to 100] 89.2 [69.1 to 92.1] 0.10 0.01
.51 [0 to 1.38] 5.77 [3.17 to 16.4] 0.15 0.01
.13 [0 to 2.66] 3.99 [2.76 to 12.2] 0.07 0.01
.05 [0 to 4.68] 1.63 [0.38 to 3.83] 0.06 0.74
7.2 [93.4 to 100] 94.8 [85.5 to 96.8] 0.046 0.12
.84 [0 to 6.63) 5.21 [3.25 to 14.5) 0.046 0.12
7 9
.46 [1.09 to 2.03] 1.90 [1.34 to 2.37] 0.46 0.74
.54 [1.21 to 2.19] 1.92 [1.24 to 2.41] 0.29 0.55
.47 [0.91 to 1.98] 1.82 [1.03 to 2.12] 0.57 0.74
.88 [0.59 to 1.40] 1.42 [0.69 to 1.83] 0.05 0.14
.47 [1.29 to 1.80] 1.49 [1.28 to 2.45] 0.36 0.74
9.7 [53.9 to6.38] 20.25 [55.1 to5.02] 0.03 0.04
.02 [9.99 to 13.0] 5.35 [10.5 to 5.99] 0.86 0.46
4.8 [54.4 to2.5] 8.60 [49.8 to4.02] 0.29 0.24
.59 [7.93 to 16.8] 4.12 [12.7 to 13.2] 0.47 0.74
3.2 [31.0 to 5.26] 23.3 [53.5 to 1.29] 0.22 0.38
.96 [20.0 to 5.15] 8.33 [11.4 to 14.0] 0.58 0.84
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DEB group, more paradoxical vasoconstriction was seen for
medium and high acetylcholine infusions in comparison to
BMS. The endothelial-independent vascular response, after
nitroglycerin infusion, was similar between all 3 groups.
Discussion
The main findings of this randomized, multicenter study
are: 1) DIOR DEB failed to demonstrate angiographic
superiority over BMS, with similar late-luminal loss and
binary restenosis rates; 2) DES showed significantly better
angiographic and clinical results compared with both DEB
and BMS; and 3) DEB had significantly more combined
uncovered and malapposed struts compared with BMS, but
less compared with the DES group.
DES were developed with the knowledge that the process
of restenosis after stent implantation is gradual and progres-
sive. Therefore, drug release from the stent was deliberately
prolonged with the use of polymer coatings, providing a
long-term and sustained drug release. On the other hand,
laboratory results have shown that even short contact
between taxol compounds with vascular smooth muscle cells
can inhibit the proliferation of these cells for a long period,
suggesting that stent-based sustained drug release may not
be necessary (19). With this knowledge, a DEB was
developed and tested in trials, which confirmed this inhib-
Figure 2 Endothelial Function Results
Comparisons of percentage of minimal luminal diameter changes, 5 mm distal
from the stent, in response to acetylcholine in incremental doses (106, 105,
and 104 mol/l/ml) and nitroglycerin. Data are expressed as mean  SEM.
Change in MLD is significantly different between BMS and DEB for the high
acetylcholine group (p  0.03). Between BMS and DES, significant differences
were seen for the low (p  0.03), medium (p  0.01), and high (p  0.04)
acetylcholine groups. All other DEB and DES points were not statistically differ-
ent from the reference BMS. MLD  minimal luminal diameter; other abbrevia-
tions as in Figure 1.itory effect on neointimal hyperplasia. This effect was
demonstrated for the currently used DIOR DEB (8,20),
and for the Sequent Please paclitaxel-coated balloon (Braun
Melsungen AG, Melsungen, Germany) (10,11).
An appealing extension of the use of DEB appeared to be
the treatment of STEMI, combining DEB with a BMS.
Specific advantages of this approach might theoretically be:
1) homogeneous administration of the drug to the vessel
wall, especially at the area of the culprit plaque, whereas the
DES delivers the drug only in the proximity of its struts;
2) better angiographic results, and hence less need for
TLR; 3) less malapposition, with potentially less stent
thrombosis with respect to DES; 4) preservation of
endothelial function with respect to DES; and 5) possibly
less prone to the potential clinical consequences in case of
shortened dual antiplatelet duration, or in patients inca-
pable of adhering to 12-month dual antiplatelet therapy.
Notwithstanding these potential advantages, the DEB
used in this study failed to prove superior angiographic
outcomes. We were not able to demonstrate a beneficial
effect of pre-treatment with DEB in STEMI. Interestingly,
however, the percentage of uncovered and malapposed
struts as seen on OCT suggest that there is a drug effect
induced by DEB that shows morphological changes com-
pared with BMS alone. The DES group showed even more
pronounced morphological changes. These findings are in
line with a recent OCT study in STEMI patients (5). These
results may suggest that the DEB did induce some effects on
neointimal proliferation as demonstrated by OCT; however,
they were insufficient to cause enough inhibition of the
process to reduce late-luminal loss as compared with the
BMS group. As has been previously demonstrated for
DES in OCT studies, effective inhibition of late-luminal
loss seems to be accompanied by specific morphological
changes, seen as uncovered and malapposed struts. These
delayed healing processes may contribute to an increased
risk of stent thrombosis (21,22). Also, the acetylcholine
testing findings in the present study point toward a drug
effect in DEB-treated patients. After incremental acetyl-
choline infusions, paradoxical vasoconstriction occurred
in the DEB- and DES-treated patients, with nonsignifi-
cantly more pronounced vasoconstriction in DEB com-
pared with DES. By contrast, endothelial function in the
BMS group was stable after incremental acetylcholine
concentrations.
A possible explanation of the findings relies on the fact
that the currently used DEB may have failed to warrant
sufficient bioavailability of paclitaxel at the lesion site (23).
A clarification for this might be the excipient used, which
consists of shellac. Recently, a side-by-side comparison in a
porcine model of various DEB relying on different excipi-
ents demonstrated differences in late-luminal loss in one
DEB over the other. In that same study, fibrin deposition
and inflammatory response were more pronounced in the
most effective DEB in comparison to a normal angioplasty
balloon and the less effective DEB (24). Although the
2336 Belkacemi et al. JACC Vol. 59, No. 25, 2012
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the study itself shows the importance of the excipient or
drug carrier in DEB technology.
A second justification might be the fact that although
mandatory per protocol, only 60% of patients in the DEB
group underwent pre-dilation with a regular balloon. Pre-
dilation before using a DEB should improve drug uptake by
the vessel wall due to the creation of micro-dissections and
thus facilitate drug transport through the intima and media.
Third, in case of calcified lesions, pre-dilation will facilitate
lesion crossing with the usually more bulky DEB and
prevent potential scrape-off of the drug. Therefore, in order
to understand the results obtained, we performed a series of
post hoc “hypothesis-generating” analyses focused on the
DEB group. Of 25 patients who had pre-dilation, the
late-luminal loss was 0.49  0.52 mm versus 0.85  0.56
mm in the 17 patients without pre-dilation in the same
DEB group (p  0.04). Finally, in 10 patients in whom
more than 1 stent was placed at the lesion site, a protocol-
mandated DEB dilation was not performed in the segment
where the additional BMS was placed. In these 10 patients
with additional BMS and without an extra DEB dilation,
the late-luminal loss was 1.01  0.75 mm versus 0.52 
0.44 mm in the 32 patients without an additional stent (i.e.,
no geographical mismatch) (p  0.01). Noticeably, 5 of
these 10 patients (50%) had a TLR.
Considering the patients who had pre-dilation with a
normal balloon and 1 stent (i.e., no geographical mismatch
of DEB and BMS), late-luminal loss was 0.74  0.60 mm
(n  29), 0.43  0.45 mm (n  19), and 0.19  0.30 (n 
35) in the BMS, DEB, and DES groups, respectively. In
this specific subgroup, the DEB had a significantly lower
late-luminal loss than the BMS subgroup (Table 6).
It remains difficult to judge the impact of these protocol
deviations on the outcomes in the DEB arm. Nevertheless,
it is important to consider these results as “hypothesis-
generating” and possibly useful when applying DEB in
future studies.
Furthermore, whereas in DES the release of paclitaxel is
regulated by a polymer coating that ensures a sustained and
gradual release over time, DEB are applied by a single short
exposure to the vessel. This may still have an impact on the
long-term outcomes in patients with de novo lesions.
Effect of Pre-Dilation and Geographical MismatcTable 6 Effect of Pre-Dilation and Geograph
BMS
Pre-dilated lesions
n 51
Late-luminal loss 0.74 0.
Pre-dilated lesions and 1 stent implanted
n 29
Late-luminal loss 0.74 0.
Values are n or mean  SD.
Abbreviations as in Table 1.However, it has been demonstrated that with a shortexposure to DEB, the amount of paclitaxel in the vessel wall
was still in a bio-effective range after 7 days (24). Therefore,
we do not believe that the half-life of paclitaxel significantly
contributed to the negative results of this study.
Study limitations. This study was powered for angio-
graphic outcomes and not aimed at detecting clinical dif-
ferences between groups. Hence, no firm conclusions can be
drawn on the safety of DEB. Since this was the first study
with DEB in STEMI, no reference late-luminal loss for the
DEB group was available for the power calculation. Because
late-luminal loss was higher in the DEB group than
assumed, the study might have been insufficiently powered
to detect smaller differences in angiographic outcomes
between the BMS and DEB groups. Therefore, even a
reduction in late-luminal loss 50% (as the original as-
sumption of this study was) could be of clinical significance
when applied to a larger cohort of patients. The OCT
outcomes with a reduction of neointimal hyperplasia in the
DEB group seem to suggest that the changes induced by
DEB might indeed have clinical significance when applied
to an appropriate number of patients. Hence, future larger
randomized studies should be performed in order to put the
current findings into perspective. Second, the study was
single blinded, thus potentially resulting in treatment bias.
Third, a risk of selection bias, which however should equally
apply to all 3 treatment arms, could not be completely ruled
out. Finally, the deviations from the protocol regarding the
lack of pre-dilation in the DEB arm, as well as the lack of
additional DEB dilation in case of additional BMS implan-
tation, may have influenced the results negatively. Never-
theless, the consequences of these post-hoc analyses should
be applied with thought and used as hypothesis-generating
outcomes.
Conclusions
Local drug delivery with a DEB to the culprit plaque of a
STEMI at the moment of highest inflammation remains an
attractive treatment opportunity. Nevertheless, the DIOR
DEB in combination with BMS failed to show angio-
graphic superiority to BMS alone, and with more evident
morphological and functional changes on OCT and acetyl-
choline testing, respectively. These morphological changes
Angiographic Outcomesismatch on Angiographic Outcomes
DEB DES
p Value
DEB vs. BMS
25 49
0.49 0.52 0.21 0.32 0.07
19 35
0.43 0.45 0.19 0.30 0.047h onical M
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60suggest a drug effect, however, one that is insufficient to
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June 19/26, 2012:2327–37 Drug-Eluting Balloon in STEMIresult in superior angiographic results. Finally, the angio-
graphic results of DES were superior to both BMS and
DEB; however, DES induced delayed healing and endo-
thelial dysfunction.
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APPENDIX
For a description of the power analysis for the OCT and endothelial function
substudy, please see the online version of this article.
